STAT+: 3 trends to watch in hospitals and health insurance in 2023
For almost three years, hospitals and health insurers have been riding the waves of the…
Category: STAT+
STAT+: Providers seeking resolution of billing disputes under the No Surprises Act cause a major backlog of cases
Health care providers are swamping the government with billing disputes under the new law that…
A letter from the executive editor: The Aduhelm Files
Dear Reader, From STAT’s first investigations in June 2021 revealing why the FDA gave the…
STAT+: ‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of Aduhelm marked by secret discussions, breaches of protocol
WASHINGTON — The Food and Drug Administration’s review and approval of a controversial Alzheimer’s drug…
STAT+: Pfizer says hemophilia B gene therapy significantly reduces bleeds
Pfizer said Thursday that its experimental gene therapy for hemophilia B significantly reduced the number…
STAT+: Eric Lander’s next act: leading a nonprofit set on solving thorny scientific challenges
In January 2021, when President Biden tapped Eric Lander to serve as the White House…
STAT+: Drug companies set sights on new Covid medicines to boost depleted arsenal
It was not that long ago that the medical community had a small arsenal of…
STAT+: The FDA’s ‘breakthrough’ program for medical devices keeps gaining steam
For medical devices in the Breakthrough Devices Program, 2022 has been a breakout year. The…
STAT+: Get ready for ‘the electric vehicles of biopharma’: Three biotech trends to watch in 2023
Predicting the future is famously a mug’s game. Between Covid-19, drug pricing legislation, and a…
STAT+: Pharmalittle: FDA approves a Genentech blood-cancer drug; Sean Parker expands his immunotherapy research empire
Good morning, Pharmalittle family! Your loyal scribe Ed Silverman is taking today off, so he…
STAT+: Parker Institute extends ‘crazy idea’ funding to two more cancer centers
With his Parker Institute for Cancer Immunotherapy, Sean Parker has been building a dream team…
STAT+: ‘Apples to apples’: How new health data rules could hold providers accountable
Last year, medical records opened up to patients. This year, they’re opening up to the…
STAT+: Apple Watch hit with import ban, but ruling remains suspended as AliveCor patent battle plays out
In the latest twist in a battle between Apple and medical device company AliveCor, the…
Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say
The latest Alzheimer’s disease treatment from Eisai and Biogen needs to be cheaper than $20,000…
STAT+: Pharmalittle: Merck pays Chinese biotech $175 million for cancer drugs; who will make a gene therapy for very sick kids?
Good morning everyone! Matthew Herper is here, filling in for Pharmalot, who is taking a…
STAT+: Backed by a longtime mental health leader, a new startup aims to build support for serious mental illness
The number of startups focused on mental health has surged in the wake of the…
STAT+: Former MIT professor tried to influence investigation of harassment at lab, report states
Former Massachusetts Institute of Technology professor David Sabatini attempted to influence a legal investigation into…
STAT+: California wants to revoke a CVS mail-order license for illegally filling opioid and ADHD prescriptions
California authorities are seeking to revoke a license held by a CVS Health mail-order pharmacy…
STAT+: Young private equity firm Catalio to absorb hedge fund HealthCor, capping off busy year of investment M&A
Two veterans of the health care investing world — Art Cohen and Joe Healey —…
STAT+: Medicare’s home hospital program may soon get a lifeline from Congress. Can it prove its worth?
A Medicare program that allowed approved health systems to bill for hospital care delivered in…
STAT+: Pharmalittle: ICER cuts cost-effective price for Pfizer Covid pill; McDonald’s sets targets to reduce antibiotic use in cattle
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Biden admin shares ownership data for thousands of hospitals, improving transparency about private equity’s stake
Citing its commitment to transparency and promoting competition, the Biden administration on Tuesday released a…
STAT+: McDonald’s adds targets for limiting antibiotic use in beef to its menu, but doesn’t say when
After being accused of backtracking on a commitment to reduce its use of medically important…
.jpg)
STAT+: Pharmalittle: Pharma wins changes in bill concerning accelerated approval; pharmacy chains restrict purchases of pediatric pain relievers
Rise and shine, everyone, another busy day is on the way. And we can tell…
STAT+: Kite to buy Tmunity Therapeutics, Carl June’s troubled CAR-T startup
Kite Pharma, Gilead’s cell therapy subsidiary, said on Tuesday it would buy Tmunity, a biotech…
.jpg)
STAT+: The list of the worst biopharma CEOs of 2022: No ‘winner,’ just accountability
I enjoy thinking about and writing the Worst CEOs of Biopharma column every year. It’s…
STAT+: Audit of FDA’s tobacco oversight underscores agency’s struggle to regulate the booming vaping market
WASHINGTON – The Food and Drug Administration’s Center for Tobacco Products is lacking clear goals…
STAT+: Gilead, Arcus anti-TIGIT drug reduces risk of lung cancer progression in mid-stage study
Gilead Sciences and Arcus Biosciences said Monday that an experimental cancer immunotherapy directed against a…
STAT+: Rare form of severe childhood obesity is linked to a single genetic mutation
Since infancy, she showed a constant desire for food. Throughout childhood, she was continually hungry…
STAT+: Pharmalittle: FDA adds Lilly diabetes drugs to shortage list; WTO delays decision on extending Covid IP waiver
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Madrigal experimental drug delivers strong results in fatty liver disease known as NASH
Madrigal Pharmaceuticals said Monday that its experimental treatment for fatty liver disease improved liver biopsies…
STAT+: Even with gene therapy on the horizon, drugmakers join hunt for new sickle cell drugs
Next year, two curative gene therapies could be approved for sickle cell disease. Yet drugmakers…
STAT+: Here are the finalists for best biopharma CEO of 2022. And a winner
It’s that time of the year again when we at STAT recognize the Best Biopharma…
STAT+: Eli Lilly diabetes drug Mounjaro in short supply, FDA says
The U.S. Food and Drug Administration has declared a shortage of Eli Lilly’s Mounjaro, the…
STAT+: Pharmalittle: AbbVie leaves pharma industry trade groups; net drug prices see big drop after inflation
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Guardant Health trial of colon cancer liquid biopsy test disappoints observers
Bay Area biotech Guardant Health on Thursday announced results from a massive trial of its…
STAT+: Drugmakers ask regulators to change standards on new Covid antibody drugs for most vulnerable
Biotech executives and a handful of academics pleaded with U.S. and European regulators on Thursday…
STAT+: Biden administration takes aim at Medicare Advantage care denials, misleading ads
The Biden administration has unveiled its plan for attacking people’s chief concerns about privatized Medicare…
STAT+: AbbVie exits major pharmaceutical industry lobbying groups
WASHINGTON — The maker of one of the world’s most profitable medicines is exiting the…
STAT+: Amid criticism over unaffordable insulin, Lilly strikes a manufacturing deal to supply Africa
In a bid to widen access to insulin in primarily low-income nations in Africa, Eli…
STAT+: Pharmalittle: U.S. prisons refuse to test and treat hepatitis C patients; HHS urges Supreme Court to reject Pfizer argument on Medicare kickbacks
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
Chief health equity officers are growing more common. But experts say companies need to empower them
A string of high-profile health companies like Teladoc and CVSHealth have hired their first chief…
STAT+: Pharmalittle: Lawmakers accuse Pfizer of ‘pure greed’ over Covid vaccine price hike; Takeda to spend $4 billion on experimental pill
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Nine in 10 health care companies with financial stress are owned by private equity
Almost 90% of the health care companies deemed to be under financial stress by a…
STAT+: ‘Right to repair’ movement gains momentum in the tightly controlled world of medical devices
When Covid-19’s first surge hit Boston in 2020, biomedical engineer Scot Mackeil knew every single…
STAT+: New Biden changes to Obamacare coverage for generics splits the industry
WASHINGTON — The Biden administration signaled Monday that it will require health plans on federal…
STAT+: Lawmakers tell Pfizer CEO to ‘back off’ on planned price hike for Covid-19 vaccine
A pair of U.S. lawmakers wrote Pfizer chief executive officer Albert Bourla that he should…
STAT+: In bid to beat Bristol Myers, Takeda buys Nimbus’ anti-inflammatory drug drug for $4 billion
Takeda Pharmaceuticals said Tuesday it will spend $4 billion and offer another $2 billion in…
STAT+: Study points to new ‘king on the block’ for treatment of chronic lymphocytic leukemia
NEW ORLEANS – One of the best therapies for some types of lymphoma and leukemia…
STAT+: Pharmalittle: Moderna and Merck vaccine lowers risk of skin cancer relapse; Cambodia halts exports of primates used for drug research
Top of the morning to you, and a fine one it is. Crystal clear blue…